Sign in

    Leonard S. Schleifer

    President and CEO at Regeneron Pharmaceuticals Inc
    Board
    Since 1988
    Age
    71 years
    Education
    Earned an M.D. and a Ph.D. in Pharmacology from the University of Virginia.
    Tenure
    Founded REGN in 1988 and has served as its President and CEO since inception, also holding the roles of Chair of the Board from 1990 to 1994 and Co-Chair since June 2023.

    Also at Regeneron Pharmaceuticals Inc

    CF
    Christopher Fenimore
    Senior Vice President, Finance and CFO
    DPVP
    Daniel P. Van Plew
    Executive Vice President and General Manager, Industrial Operations and Product Supply
    JP
    Jason Pitofsky
    Vice President, Controller

    About

    Leonard S. Schleifer has built a distinguished career in the biopharmaceutical industry by uniquely blending his expertise in medicine and research with innovative business leadership. His background in neurology and pharmacology has provided him with a solid foundation to drive complex research and strategic initiatives, positioning him as a key figure in groundbreaking drug development.

    After founding REGN in 1988, he played an instrumental role in transforming the company into a leader in the field, overseeing the development of numerous innovative therapies and pioneering technologies. His leadership journey includes significant board-level responsibilities that have further underscored his commitment to excellence and continuous innovation in the biotechnology sector.

    In addition to his professional achievements, his deep understanding of both the scientific and business aspects of the industry has been widely recognized, contributing to his reputation as an influential and visionary leader. His work continues to drive the company's success in an increasingly competitive market, reflecting his enduring impact on the biopharmaceutical landscape.

    $REGN Performance Under Leonard S. Schleifer

    Past Roles

    OrganizationRoleDate RangeDetails
    Regeneron Pharmaceuticals, Inc.Chair of the Board1990 - 1994Served as Chair prior to his current executive roles

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$1,875,415 AnnualFixed base salary component
    All Other Compensation$2,032,977 AnnualIncludes: Life Insurance Premiums ($20,724 ), Disability Insurance Premiums ($8,465 ), Medical Malpractice Insurance Premiums ($28,822 ), 401(k) Matching ($15,000 ), Tax and Financial Planning Advisory Services ($11,200 ), Hart-Scott-Rodino Filing Fees ($400,000 ), Tax Reimbursement ($417,160 ), Personal Use of Company-Provided Aircraft ($250,000 ), Security Services ($881,606 )

    Performance Compensation

    Data from  FY 2023

    Cash-Based Performance Incentive

    Metric NameValue
    Base Salary$1,875,415
    Cash Incentive Target120% of Base Salary
    Corporate Performance Multiplier1.9
    Total Cash Incentive Payout$4,275,946
    Vesting ScheduleNot Applicable (cash-based)
    Evaluation Period2023

    Calculation Detail:

    Base Salary × Cash Incentive Target × Corporate Performance Multiplier = Total Cash Incentive Payout. For example, $1,875,415 × 1.20 × 1.9 = $4,275,946.

    Additional Information:

    • No individual performance multiplier was applied.
    • The 2023 annual cash incentive pool was adjusted based on the company’s performance against predefined R&D-related goals.